Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Some cancers linked to extremely low frequency electromagnetic fields

Some cancers linked to extremely low frequency electromagnetic fields

Diets high in salt may increase stomach ulcers

Diets high in salt may increase stomach ulcers

High salt intake increases gene activity in the ulcer-causing bacterium Helicobacter pylori

High salt intake increases gene activity in the ulcer-causing bacterium Helicobacter pylori

FDA approves VELCADE plus DOXIL combination for multiple myeloma

FDA approves VELCADE plus DOXIL combination for multiple myeloma

Scientists develop method to track immune system enzyme in live animals

Scientists develop method to track immune system enzyme in live animals

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

PET-CT is better for early detection of muscular lymphoma than CT alone

PET-CT is better for early detection of muscular lymphoma than CT alone

Hepatitis C increases risk for non-Hodgkin's lymphoma

Hepatitis C increases risk for non-Hodgkin's lymphoma

Rituximab reduces disease activity in multiple sclerosis

Rituximab reduces disease activity in multiple sclerosis

World's first microRNA knockout mouse

World's first microRNA knockout mouse

Johns Hopkins team stops form of blood cancer in its tracks

Johns Hopkins team stops form of blood cancer in its tracks

FDA panel recommends new HIV drug Maraviroc

FDA panel recommends new HIV drug Maraviroc

Naturally occurring compound found in many fruits and vegetables as well as red wine, selectively kills leukemia cells

Naturally occurring compound found in many fruits and vegetables as well as red wine, selectively kills leukemia cells

New drug Maraviroc an alternative in the fight against HIV

New drug Maraviroc an alternative in the fight against HIV

M. D. Anderson wins $8.3-million to research environmental causes of major diseases

M. D. Anderson wins $8.3-million to research environmental causes of major diseases

Aspirin use linked to moderate drop in cancer risk

Aspirin use linked to moderate drop in cancer risk

Novel targeted therapy effectively treats acute leukemia

Novel targeted therapy effectively treats acute leukemia

New method predicts hip joint decay from chemotherapy

New method predicts hip joint decay from chemotherapy

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.